-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Moccia and others assessed the disease and treatment characteristics of patients with early-stage typical Hodgkin's lymphoma (ES-HL) recurrence after first-line risk adaptation, comparing second-line therapy, high-dose chemotherapy, autobiographical stem cell transplantation (ASCT) and conventional chemotherapy (CTx).
patients were ES-HL patients who relapsed after treatment in the Hodgkin's hd10-HD13 trial in Germany.
researchers compared relapsed progression-free survival (PFS), or secondary PFS, among patients treated with ASCT or CTx, and performed a sensitivity analysis of total survival (OS).
174 patients who relapsed after treatment (53 in the HD10 trial and 121 in the HD13 trial).
recurrence occurs 12 months after the first treatment, mainly for stage I-II diseases.
of the 172 patients who had received second-line treatment, 85 received CTx treatment (49 per cent), 70 received ASCT treatment (41 per cent), 11 received radiotherapy (6 per cent) and 4 received palliative monotherapy (2 per cent).
CTx is mainly a joint programme of bolemycin, etoposide, amycin cyclophosphamide, chrysotyl chrysotide, acetate, methotrexate and strong pine (BEACOPP (68%)), followed by a joint programme of amycin, bolemycin, chrysotycin and dakabazine (19%), with the other programme accounting for 13%.
PFS (HR 3.0) was shorter for patients over the age of 60 at the time of diagnosis, mostly with CTx (67%) and less with ASCT (16%).
CTx and ASCT are calibrated according to age and ASCT shortcomings, there is no significant difference between secondary PFS (HR 0.7).
patients with HD13 trial age ≤60 years of age, the two-year secondary PFS rate with CTx treatment was 94%, compared with 83.3% for ASCT treatment.
other sensitivity analyses, including OS, have achieved similar results.
, after the initial treatment of ES-HL patients, relapses occur more than 12 months later.
combination chemotherapy program, such as BEACOPP, is a common treatment for patients with ES-HL recurrence and may be a reasonable treatment option.
.
